Nigeria's Fidson partners with US firms for Lodonal

Leading Nigerian drugmaker Fidson Healthcare has entered into a partnership with US firms, Immune Therapeutics, GB Pharma and American Hospitals & Resort (AHAR) for the marketing and distribution of a new product, Lodonal (naltrexone hydrochloride), a patent-protected product that is indicated for the management of patients with immune-compromising diseases.

The partnership will leverage Fidson’s strong and experienced marketing base, robust distribution channels and efficient customer and technical support services to promote Lodonal in Nigeria. The distribution will become effective, upon completion of the ongoing NAFDAC (the National Agency for Food and Drug Administration and Control) approved 90‐day bridging trial evaluating the efficacy and safety of the product.

Fidelis Ayebae, managing director of the Nigerian company, said: “Fidson is truly excited about this collaboration with Immune Therapeutics and GB Pharma/AHAR. We know that success in this industry going into the future will be dependent on having the right partnerships, and we could not have asked for better partners at this stage of our growth. The international experience of Immune Therapeutics and GB Pharma/AHAR in different markets, and their strong commitment to research will be of immense benefit to Fidson. Likewise, Fidson’s towering presence in the Nigeria Pharma space will open a great door for the group to access one of the biggest and most rewarding markets in Africa”.